A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial.

BACKGROUND & AIMS Population screening and treatment of Helicobacter pylori has been advocated as a means of reducing mortality from gastric cancer, as well as dyspepsia and dyspepsia-related resource use. Previous programs have failed to demonstrate a significant effect on mortality or resource use, but follow-up was only for 1 or 2 years. We aimed to determine the effect of screening for H pylori on dyspepsia and dyspepsia-related resource use over 10 years. METHODS H pylori-positive individuals, aged 40-49 years, enrolled in a community screening program, randomized to eradication therapy or placebo in 1994, were sent a validated dyspepsia questionnaire by mail 10 years later, and primary care records were reexamined. Consultation, referral, prescribing, and investigation data related to dyspepsia were extracted. United Kingdom costs were applied to derive total cost per person (1 pound = 1.8 dollars). RESULTS Of 2324 original participants, 1864 (80%) were traced and contacted. Of these, 1086 (47%) responded, and 919 (40%) agreed to a review of their primary care records. There was a 10-year mean saving in total dyspepsia-related costs of 117 dollars per person (95% confidence interval [CI] = 11 dollars-220 dollars, P = .03) with eradication therapy. Those symptomatic at baseline showed a nonsignificant trend toward resolution of symptoms at 10 years with eradication therapy (relative risk of remaining symptomatic, 0.89; 95% CI: 0.77-1.03). CONCLUSIONS There were significant reductions in total dyspepsia-related health care costs. The savings made were greater than the initial cost of H pylori screening and treatment.

[1]  D. Forman,et al.  Eradication Therapy in Helicobacter pylori Positive Peptic Ulcer Disease: Systematic Review and Economic Analysis , 2004, The American Journal of Gastroenterology.

[2]  D. Forman,et al.  Helicobacter pylori infection and gastric cancer--for want of more outcomes. , 2004, JAMA.

[3]  S. Leung,et al.  Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. , 2004, JAMA.

[4]  J. Lee,et al.  (Helicobacter pylori Eradication to Prevent Gastric Cancer in a High-Risk Region of China.) , 2004 .

[5]  D. Forman,et al.  An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews , 2003, American Journal of Gastroenterology.

[6]  P. Moayyedi,et al.  How can the current strategies for Helicobacter pylori eradication therapy be improved? , 2003, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[7]  Susan R. Wilson,et al.  Validation of the short-form leeds dyspepsia questionnaire (SF-LDQ) in a community setting , 2003 .

[8]  A. Axon Gastric cancer and Helicobacter pylori , 2002 .

[9]  P. Moayyedi,et al.  Clinical and economic consequences of dyspepsia in the community , 2002, Gut.

[10]  M. Drummond,et al.  The cost‐effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial , 2002, Alimentary pharmacology & therapeutics.

[11]  A. Helicobacter,et al.  Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts , 2001, Gut.

[12]  J. Mason,et al.  Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial , 2000, The Lancet.

[13]  P. Moayyedi,et al.  The Leeds Dyspepsia Questionnaire: a valid tool for measuring the presence and severity of dyspepsia , 1998, Alimentary pharmacology & therapeutics.

[14]  A. Sonnenberg,et al.  Medical decision models of Helicobacter pylori therapy to prevent gastric cancer , 1998, Alimentary pharmacology & therapeutics.

[15]  F. Mégraud,et al.  How should Helicobacter pylori infection be diagnosed? , 1997, Gastroenterology.

[16]  P. Moayyedi,et al.  Significance of Helicobacter pylori infection and gastric cancer: implications for screening. , 1997, Gastrointestinal endoscopy clinics of North America.

[17]  Douglas K Owens,et al.  Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials , 1996, The Lancet.

[18]  E. Kuipers,et al.  Seroconversion for Helicobacter pylori , 1993, The Lancet.

[19]  J. Parsonnet Helicobacter pylori and gastric cancer. , 1993, Gastroenterology clinics of North America.